Kunjal Modi, MD
Ophthalmology · Jersey City, NJNPI 1548689904
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,600 of the $23,954 with a category attached, or 61.0%. 23 manufacturers reported payments, led by Sight Sciences, Inc. at 36.9% of the total. 2025 is the largest year on record at $9,957, more than ten times the $244 reported in 2019. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $68.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$9K
- NEW World Medical,inc.$7K
- AbbVie$2K
- Bausch & Lomb Americas Inc.$2K
- Sun Pharmaceutical Industries Inc.$949
- Biotissue Holdings Inc.$907
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$14,60061%
- Food & beverage$9,35439%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 20 | $8,834 |
| NEW World Medical,inc. | 15 | $7,362 |
| AbbVie(2 entities) | 116 | $2,089 |
| Bausch & Lomb Americas Inc. | 58 | $1,521 |
| Sun Pharmaceutical Industries Inc. | 42 | $949 |
| Biotissue Holdings Inc. | 19 | $907 |
| Tarsus Pharmaceuticals, Inc. | 5 | $364 |
| Glaukos Corporation | 3 | $305 |
| Aerie Pharmaceuticals, Inc. | 7 | $293 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $237 |
| Alcon | 11 | $186 |
| Kala Pharmaceuticals, Inc. | 10 | $147 |
| Ocular Therapeutix, Inc. | 9 | $143 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $126 |
| Dompe US, Inc. | 1 | $108 |
| Travere Therapeutics, Inc. | 6 | $95 |
| Oyster Point Pharma, Inc. | 5 | $80 |
| Eyevance Pharmaceuticals LLC | 3 | $58 |
| Mallinckrodt Hospital Products Inc. | 2 | $37 |
| Hologic Sales And Service, LLC | 1 | $36 |
| Sandoz | 1 | $34 |
| Coherus Oncology, Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$8,594
- SION SURGICAL INSTRUMENT$8,594
- Kahook Dual Blade$4,019
- Clearpath$4,019
- Ahmed Glaucoma Valve$4,019
- Streamline$4,019
- enVista MX60 IOL$918
- AmnioGraft$508
- CEQUA$462
- Prokera$401
- XDEMVY$326
- DURYSTA$245
- iDose$166
- CATALYS SYSTEM$139
- Rocklatan$119
- Rhopressa$119
- LUMIGAN$108
- COMBIGAN$108
- Oxervate$108
How this compares
$23,954 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 357 | $167,425 |
| RestasisCyclosporine | 93 | $110,448 |
| CequaCyclosporine | 46 | $46,586 |
| RhopressaNetarsudil Mesylate | 102 | $44,796 |
| CombiganBrimonidine Tartrate/Timolol | 125 | $40,280 |
| XiidraLifitegrast | 36 | $38,099 |
| VyzultaLatanoprostene Bunod | 76 | $31,113 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 140 | $22,130 |
| Prednisolone Acetate | 618 | $19,997 |
| Travoprost | 129 | $18,631 |
| Ketorolac Tromethamine | 549 | $18,452 |
| Alphagan PBrimonidine Tartrate | 64 | $18,317 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 64 | $17,099 |
| Cyclosporine | 16 | $14,847 |
| Latanoprost | 783 | $7,924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $2,089 | $336,470639 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $1,521 | $69,212112 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $949 | $46,58646 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $293 | $44,796102 claims |
| AlconSimbrinza | $186 | $17,09964 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $58 | $3,28614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Jersey City
- Scott WalsmanJersey City$93K
- Ganesh RauJersey City$11K
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.